BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

860 related articles for article (PubMed ID: 30138971)

  • 1. [The clinical significance of myositis-specific antibodies in polymyositis/dermatomyositis associated interstitial lung diseases].
    Xie MM; Yan X; Li H; Ding JJ; Gui XH; Liu Y; Wang YS; Chen ZY; Cai HR
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Aug; 41(8):616-621. PubMed ID: 30138971
    [No Abstract]   [Full Text] [Related]  

  • 2. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].
    Xie MM; Zou RY; Li Y; Liu Y; Chen LL; Liu XQ; Zhao Q; Ding JJ; Chen ZY; Cai HR
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):765-770. PubMed ID: 31594111
    [No Abstract]   [Full Text] [Related]  

  • 4. Myositis-specific antibodies and clinical characteristics in patients with autoimmune inflammatory myopathies: reported by the Argentine Registry of Inflammatory Myopathies of the Argentine Society of Rheumatology.
    Gómez GN; Pérez N; Braillard Poccard A; Gómez RA; Costi AC; García MA; Viola M; Benitez A; Aciar MM; Crespo Espíndola M; Yucra D; Cosatti MA; Pisoni C; Capelusnik D; Lojo MN; Barrios BI; Rivero M; Kisluk B; Granel A
    Clin Rheumatol; 2021 Nov; 40(11):4473-4483. PubMed ID: 34159491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease.
    Li L; Wang H; Wang Q; Wu C; Liu C; Zhang Y; Cheng L; Zeng X; Zhang F; Li Y
    J Neurol Sci; 2019 Feb; 397():123-128. PubMed ID: 30616054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
    Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Myositis-Associated Interstitial Lung Disease.
    Fujisawa T
    Medicina (Kaunas); 2021 Apr; 57(4):. PubMed ID: 33916864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.
    Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G
    Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
    Chen F; Li S; Wang T; Shi J; Wang G
    Am J Med Sci; 2018 Jan; 355(1):48-53. PubMed ID: 29289262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies.
    Misra AK; Wong NL; Healey TT; Lally EV; Shea BS
    BMC Pulm Med; 2021 Nov; 21(1):370. PubMed ID: 34775966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
    Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
    J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease.
    Gono T; Kaneko H; Kawaguchi Y; Hanaoka M; Kataoka S; Kuwana M; Takagi K; Ichida H; Katsumata Y; Ota Y; Kawasumi H; Yamanaka H
    Rheumatology (Oxford); 2014 Dec; 53(12):2196-203. PubMed ID: 24970922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Characteristics and Risk Factors of Polymyositis and Dermatomyositis Combined with Interstitial Lung Disease in Patients Residing in the Northeast Sichuan Province of China.
    Li T; Tang ZY; Zhang QB; Xiao FN; Jian GL; Xie Y; Guo JW; Qing YF
    Curr Rheumatol Rev; 2023; 19(4):455-462. PubMed ID: 37005523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases.
    Fujisawa T; Hozumi H; Kono M; Enomoto N; Nakamura Y; Inui N; Nakashima R; Imura Y; Mimori T; Suda T
    Respir Investig; 2017 Mar; 55(2):130-137. PubMed ID: 28274528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis/dermatomyositis].
    Wang PZ; Guan JL; Han XH
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Jun; 31(6):417-20. PubMed ID: 19031800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Jo-1 antibody in patients with polymyositis/dermatomyositis.
    Leu CC; Lan JL
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1992 Feb; 25(1):41-7. PubMed ID: 1306148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
    Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
    Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort.
    Chen F; Wang J; Zhang P; Zuo Y; Ye L; Wang G; Shu X
    Front Immunol; 2022; 13():879266. PubMed ID: 35603153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis/dermatomyositis.
    Temmoku J; Sato S; Fujita Y; Asano T; Suzuki E; Kanno T; Furuya MY; Matsuoka N; Kobayashi H; Watanabe H; Koga T; Shimizu T; Kawakami A; Migita K
    Medicine (Baltimore); 2019 May; 98(20):e15578. PubMed ID: 31096460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.